Etiology and frequency of rhabdomyolysis

被引:34
作者
Black, C [1 ]
Jick, H [1 ]
机构
[1] Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA
来源
PHARMACOTHERAPY | 2002年 / 22卷 / 12期
关键词
D O I
10.1592/phco.22.17.1524.34130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objectives. To describe the etiology and characteristics of patients with clinically diagnosed rhabdomyolysis in the United Kingdom General Practice Research Database (GPRD), and to estimate the risk of rhabdomyolysis in general and that associated with lipid-lowering agents in particular. Design. Retrospective analysis. Setting. The GPRD. Patients. A base population of patients aged 20-75 years. Intervention. Patients hospitalized with a computer-recorded code for acute myositis or myoglobinuria, or with "rhabdo" recorded in free text comments were reviewed for evidence of rhabdomyolysis. Lipid-lowering treatment among the base population also was calculated. Measurements and Main Results. We identified 25 patients with rhabdomyolysis among 2.5 million in the base population between 1990 and 1999. Seven cases (28%) occurred after a drug overdose and 5 (20%) after septicemia. Among the 2935 concurrent users of statin and fibrate agents, one developed rhabdomyolysis. Conclusion. Only 25 patients out of 2.5 million were found to have rhabdomyolysis. Of those, only one patient was taking a statin and fibrate concurrently, out of almost 3000 concurrent users. The free-text comments field in the GPRD helped to identify patients with rhabdomyolysis.
引用
收藏
页码:1524 / 1526
页数:3
相关论文
共 10 条
[1]   Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil [J].
Alexandridis, G ;
Pappas, GA ;
Elisaf, MS .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (03) :261-262
[2]  
Charatan F, 2001, BRIT MED J, V323, P359, DOI 10.1136/bmj.323.7309.359
[3]   THE SPECTRUM OF RHABDOMYOLYSIS [J].
GABOW, PA ;
KAEHNY, WD ;
KELLEHER, SP .
MEDICINE, 1982, 61 (03) :141-152
[4]   Lipid-lowering drugs and risk of myopathy:: A population based follow-up study [J].
Gaist, D ;
Rodríguez, LAG ;
Huerta, C ;
Hallas, J ;
Sindrup, SH .
EPIDEMIOLOGY, 2001, 12 (05) :565-569
[5]   Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease [J].
Hino, I ;
Akama, H ;
Furuya, T ;
Ueda, H ;
Taniguchi, A ;
Hara, M ;
Kashiwazaki, S .
ARTHRITIS AND RHEUMATISM, 1996, 39 (07) :1259-1260
[6]   VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM [J].
JICK, H ;
JICK, SS ;
DERBY, LE .
BRITISH MEDICAL JOURNAL, 1991, 302 (6779) :766-768
[7]  
JICK H, 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607
[8]   Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin [J].
Mogyorósi, A ;
Bradley, B ;
Showalter, A ;
Schubert, ML .
JOURNAL OF INTERNAL MEDICINE, 1999, 246 (06) :599-602
[9]   Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study [J].
Pedersen, TR ;
Berg, K ;
Cook, TJ ;
Faergeman, O ;
Haghfelt, T ;
Kjekshus, J ;
Miettinen, T ;
Musliner, TA ;
Olsson, AG ;
Pyorala, K ;
Thorgeirsson, G ;
Tobert, JA ;
Wedel, H ;
Wilhelmsen, L .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (18) :2085-2092
[10]   Rhabdomyolysis and myohemoglobinuric acute renal failure [J].
Zager, RA .
KIDNEY INTERNATIONAL, 1996, 49 (02) :314-326